{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:31:13Z","timestamp":1765827073687,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.rmed.2013.01.017","type":"journal-article","created":{"date-parts":[[2013,3,13]],"date-time":"2013-03-13T14:32:32Z","timestamp":1363185152000},"page":"768-777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection"],"prefix":"10.1016","volume":"107","author":[{"given":"Jos\u00e9 Ma.","family":"Pina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Clotet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Rosa","family":"Sala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricio","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lluis","family":"Salleras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"volume":"vol. 15\u201395","year":"2002","author":"Rieder","key":"10.1016\/j.rmed.2013.01.017_bib1"},{"key":"10.1016\/j.rmed.2013.01.017_bib2","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1098\/rsif.2007.1138","article-title":"Eliminating human tuberculosis in the twenty-first century","volume":"5","author":"Dye","year":"2008","journal-title":"J R Soc Interface"},{"key":"10.1016\/j.rmed.2013.01.017_bib3","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial","volume":"60","author":"International Union Against Tuberculosis. Committee on Prophylaxis","year":"1982","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.rmed.2013.01.017_bib4","first-page":"1","article-title":"Statement committee on latent tuberculosis infection. Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"49","author":"American Thoracic Society\/Centers for Disease Control","year":"2000","journal-title":"MMWR"},{"key":"10.1016\/j.rmed.2013.01.017_bib5","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1164\/rccm.200901-0153OC","article-title":"Costs and cost effectiveness of four regimens for latent tuberculosis infection","volume":"179","author":"Holland","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2013.01.017_bib6","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.5588\/ijtld.10.0575","article-title":"Potential cost-effectiveness of rifampin vs isoniazid for latent tuberculosis: implications for future clinical trials","volume":"15","author":"Esfahani","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.rmed.2013.01.017_bib7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1378\/chest.09-0394","article-title":"Latent TB infection treatment. Acceptance and completion in the Unites States and Canada","volume":"137","author":"Horsburgh","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2013.01.017_bib8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.arbres.2010.02.010","article-title":"Consensus document on the diagnosis, treatment and prevention of tuberculosis","volume":"46","author":"Gonz\u00e1lez-Mart\u00edn","year":"2010","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.rmed.2013.01.017_bib9","series-title":"Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for the prevention and\u00a0control","first-page":"191","article-title":"Treatment regimens for latent tuberculosis infection","author":"National Collaborating Centre for Chronic Conditions","year":"2011"},{"issue":"RR-15","key":"10.1016\/j.rmed.2013.01.017_bib10","first-page":"1","article-title":"Guidelines for the Investigation of contacts of persons with infectious tuberculosis. Recommendations from the National tuberculosis Controllers Association and CDC","volume":"54","author":"National Tuberculosis Controllers Association and CDC","year":"2005","journal-title":"MMWR"},{"key":"10.1016\/j.rmed.2013.01.017_bib11","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"Documents. An official statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"American Thoracic Society","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"volume":"19\u201330","year":"2008","author":"Muennig","key":"10.1016\/j.rmed.2013.01.017_bib12"},{"key":"10.1016\/j.rmed.2013.01.017_bib13","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1111\/j.1469-0691.2010.03331.x","article-title":"Understanding cost-effectiveness","volume":"16","author":"Zilberberg","year":"2010","journal-title":"Clin Microbiol Infect"},{"year":"2006","series-title":"Informaci\u00f3n de medicamentos autorizados en Espa\u00f1a. Ministerio de Sanidad y Consumo. Gu\u00eda de prescripci\u00f3n terap\u00e9utica (GPT)","author":"Agencia Espa\u00f1ola de Medicamentos","key":"10.1016\/j.rmed.2013.01.017_bib14"},{"key":"10.1016\/j.rmed.2013.01.017_bib15","unstructured":"Institut Catal\u00e0 de la Salut. Resoluci\u00f3 slt\/434\/2008, de 12 de Febrer: Revisi\u00f3 de preus p\u00fablics corresponents als serveis sanitaris que presta l\u2019Institut Catal\u00e0 de la Salut. Diari Oficial de la Generalitat de Catalunya N\u00fam. 5076, 22 February 2008."},{"issue":"RR-11","key":"10.1016\/j.rmed.2013.01.017_bib17","first-page":"1","article-title":"Treatment of tuberculosis","volume":"52","author":"American Thoracic Society, CDC, Infectious Disease Society of America","year":"2003","journal-title":"MMWR"},{"year":"2009","series-title":"Norma estatal de los AP GRD v23","author":"Agencia de Calidad del Servicio Nacional de Salud. Instituto de Informaci\u00f3n Sanitaria","key":"10.1016\/j.rmed.2013.01.017_bib18"},{"year":"2008","series-title":"Anti-tuberculosis drug resistance in the world","author":"World Health Organization","key":"10.1016\/j.rmed.2013.01.017_bib19"},{"key":"10.1016\/j.rmed.2013.01.017_bib20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1017\/S0950268897007917","article-title":"The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection","volume":"119","author":"Vynnycky","year":"1997","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.rmed.2013.01.017_bib21","first-page":"1112","article-title":"Risk factors for developing tuberculosis: a 12-year follow-up of contacts of tuberculosis cases","volume":"14","author":"Mor\u00e1n-Mendoza","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.rmed.2013.01.017_bib22","series-title":"Tuberculosis and nontuberculosis mycobacterial infections","first-page":"3","article-title":"Epidemiology and host factors","author":"Dutt","year":"1999"},{"key":"10.1016\/j.rmed.2013.01.017_bib23","series-title":"Reichman and Hershfield's tuberculosis. A comprehensive, international approach","first-page":"793","article-title":"Tuberculosis transmission and infection control in congregate settings","author":"Nardel","year":"2006"},{"key":"10.1016\/j.rmed.2013.01.017_bib24","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1164\/rccm.200405-584PP","article-title":"Considering the role of four months of rifampin in the treatment of latent tuberculosis infection","volume":"170","author":"Reichman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"volume":"115\u2013177","year":"2006","author":"Straus","key":"10.1016\/j.rmed.2013.01.017_bib25"},{"key":"10.1016\/j.rmed.2013.01.017_bib26","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1157\/13116320","article-title":"Adherence and effectiveness of the treatment of latent tuberculosis infection with isoniazid for 9 months in a cohort of 755 patients","volume":"130","author":"Pina-Guti\u00e9rrez","year":"2008","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.rmed.2013.01.017_bib27","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1157\/13089668","article-title":"Factors associated with latent tuberculous infection in immigrants less than 35 years old","volume":"24","author":"Bran","year":"2006","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.rmed.2013.01.017_bib28","doi-asserted-by":"crossref","first-page":"w13240","DOI":"10.4414\/smw.2011.13240","article-title":"Adverse effects and adherence to treatment of rifampin 4 months vs isoniazid 6 months for latent tuberculosis. A retrospective analysis","volume":"141","author":"Fresard","year":"2011","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.rmed.2013.01.017_bib29","doi-asserted-by":"crossref","first-page":"633","DOI":"10.5588\/ijtld.11.0504","article-title":"Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial","volume":"16","author":"Chan","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.rmed.2013.01.017_bib30","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1086\/600394","article-title":"A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis in a public health clinic in Central Massachusetts","volume":"49","author":"Young","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmed.2013.01.017_bib31","first-page":"36","article-title":"Madras\/British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong","volume":"145","author":"Hong Kong Chest Service\/Tuberculosis Research Centre","year":"1992","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2013.01.017_bib32","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1164\/ajrccm\/140.5.1189","article-title":"Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide","volume":"140","author":"Lecoeur","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.rmed.2013.01.017_bib33","article-title":"Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection","author":"Pina","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.rmed.2013.01.017_bib34","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1183\/09031936.00120908","article-title":"LTBI: latent tuberculosis infection or lasting inmune response to M tuberculosis? A TBNET consensus statement","volume":"33","author":"Mack","year":"2008","journal-title":"Eur Respir J"},{"year":"1995","series-title":"M\u00e9todos de investigaci\u00f3n aplicados a la atenci\u00f3n primaria de salud","author":"Argim\u00f3n","key":"10.1016\/j.rmed.2013.01.017_bib35"},{"key":"10.1016\/j.rmed.2013.01.017_bib36","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?","volume":"2","author":"Comstock","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.rmed.2013.01.017_bib37","first-page":"1235","article-title":"Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada","volume":"12","author":"Hirsch-Moverman","year":"2008","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611113000437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611113000437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:26:57Z","timestamp":1760614017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611113000437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0954611113000437"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2013.01.017","relation":{},"ISSN":["0954-6111"],"issn-type":[{"type":"print","value":"0954-6111"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2013.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}